CAMP · Camp4 Therapeutics Corp · Metrics
$3.30
-0.09 (-2.65%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$207.09M
Shares
62.75M
Volume · Oct 23
284.95K
Avg daily vol (3M)
262.71K
CAMP metrics
71 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$3.30
Market cap
$207.09M
Price action
20 metricsPrice change (1W)
+4.1%
Price change (30D)
-15.8%
Price change (3M)
+4.4%
Price change (6M)
-25.7%
Price change (YTD)
-46.2%
Price change (1Y)
-5.2%
Trailing year
Price change (5Y)
—
52-week high
$7.13
52-week low
$2.90
Change from 52-week high
-53.7%
Change from 52-week low
+13.8%
Annualized volatility
108.9%
Annualized volatility (3M)
96.3%
Beta
2.0
RSI (14D)
38.2
Price vs SMA 50
-17.8%
Price vs SMA 200
-22.9%
Avg volume (3M)
262,706
Relative volume
1.1
Average dollar volume
$1.08M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
62.75M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
28.6×
reciprocal yield 3.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
49.1×
reciprocal yield 2.0%
P / book
—
FCF yield
-13.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-51.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
37.6×
reciprocal yield 2.7%
EV / revenue historical average (5Y)
37.6×
reciprocal yield 2.7%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2024-11-21
Profitability
9 metricsGross margin
—
Operating margin
-1,254.2%
Trailing 12 months
Net margin
-2,543.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$52.88M
Net income (TTM)
−$107.24M
Trailing 12 months
Diluted EPS (TTM)
$-2.31
FCF margin
-681.2%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+18.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$4.22M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+187.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-114.8%
Debt / equity
—
Current ratio
4.7
EBITDA (TTM)
−$51.04M
Free cash flow (TTM)
−$28.72M
Quick ratio
4.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$86.40M
Latest balance sheet
Cash & equivalents
$86.40M
Total assets
$93.43M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$28.59M
Capital expenditures (TTM)
$129,000
R&D (TTM)
$38.69M
SG&A (TTM)
—
Stock compensation (TTM)
$5.54M
R&D / revenue
917.7%
Stock compensation / revenue
131.4%
Ownership (13F)
9 metrics13F filers
61
13F filer change QoQ
+14
Institutional ownership
66.4%
Conviction holders (share of 13F filers)
6.6%
Crowding (high-turnover and private-fund holders)
38.4%
Private-fund adviser ownership
38.4%
Active holders' share change QoQ
-1.2%
Holder tenure
4.5
Price vs estimated holder cost
+8.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
4.6%
Short interest
3 metricsShort interest
2.3%
Latest settlement · 5.1 days to cover
Days to cover
5.1d
Short-squeeze score
66 / 100
Insider activity
2 metricsNet insider buying (90D)
−$2.40M
Insider-sentiment score
38 / 100
Risk flags
1 metricsGoing concern
—